Related Experiment Videos
Abstract:
Rui-Hua Xu completed the REGOTORI trial that showed a novel combination regimen, regorafenib plus toripalimab, improved the efficacy and survival of refractory metastatic colorectal cancer, and found high-abundance Fusobacterium negatively predicted response and survival. In this Q&A, he discusses his academic journey and the future directions of his field.